Neuroethics 1 (1):45-54 (2008)

Many drugs have therapeutic off-label uses for which they were not originally designed. Some drugs designed to treat neuropsychiatric and other disorders may enhance certain normal cognitive and affective functions. Because the long-term effects of cognitive and affective enhancement are not known and may be harmful, a precautionary principle limiting its use seems warranted. As an expression of autonomy, though, competent individuals should be permitted to take cognition- and mood-enhancing agents. But they need to be aware of the risks in chronic use of these agents and to take responsibility for their effects. A reasonable middle ground between these positions is to warn those who choose to enhance that doing so entails risks.
Keywords Authenticity  Anxiety  Attention  Memory  Methylphenidate  Modafinil  Propranolol
Categories (categorize this paper)
DOI 10.1007/s12152-008-9005-9
Edit this record
Mark as duplicate
Export citation
Find it on Scholar
Request removal from index
Revision history

Download options

PhilArchive copy

Upload a copy of this paper     Check publisher's policy     Papers currently archived: 72,564
Through your library

References found in this work BETA

The Constitution of Selves.Marya Schechtman (ed.) - 1996 - Cornell University Press.
Neuroethics: Challenges for the 21st Century.Neil Levy - 2007 - Cambridge University Press.

View all 14 references / Add more references

Citations of this work BETA

Toward a Legitimate Public Policy on Cognition-Enhancement Drugs.Veljko Dubljevic - 2012 - American Journal of Bioethics Neuroscience 3 (3):29-33.

View all 20 citations / Add more citations

Similar books and articles


Added to PP index

Total views
148 ( #81,329 of 2,533,483 )

Recent downloads (6 months)
1 ( #391,480 of 2,533,483 )

How can I increase my downloads?


My notes